Proteomic Basis of the Antibody Response to Monkeypox Virus Infection Examined in Cynomolgus Macaques and a Comparison to Human Smallpox Vaccination by Keasey, Sarah et al.
Proteomic Basis of the Antibody Response to Monkeypox
Virus Infection Examined in Cynomolgus Macaques and a
Comparison to Human Smallpox Vaccination
Sarah Keasey
1, Christine Pugh
1, Alexander Tikhonov
2, Gengxin Chen
2, Barry Schweitzer
2, Aysegul
Nalca
1, Robert G. Ulrich
1*
1United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, United States of America, 2Life Technologies, Carlsbad, California, United
States of America
Abstract
Monkeypox is a zoonotic viral disease that occurs primarily in Central and West Africa. A recent outbreak in the United
States heightened public health concerns for susceptible human populations. Vaccinating with vaccinia virus to prevent
smallpox is also effective for monkeypox due to a high degree of sequence conservation. Yet, the identity of antigens within
the monkeypox virus proteome contributing to immune responses has not been described in detail. We compared antibody
responses to monkeypox virus infection and human smallpox vaccination by using a protein microarray covering 92–95%
(166–192 proteins) of representative proteomes from monkeypox viral clades of Central and West Africa, including 92%
coverage (250 proteins) of the vaccinia virus proteome as a reference orthopox vaccine. All viral gene clones were verified
by sequencing and purified recombinant proteins were used to construct the microarray. Serum IgG of cynomolgus
macaques that recovered from monkeypox recognized at least 23 separate proteins within the orthopox proteome, while
only 14 of these proteins were recognized by IgG from vaccinated humans. There were 12 of 14 antigens detected by sera
of human vaccinees that were also recognized by IgG from convalescent macaques. The greatest level of IgG binding for
macaques occurred with the structural proteins F13L and A33R, and the membrane scaffold protein D13L. Significant IgM
responses directed towards A44R, F13L and A33R of monkeypox virus were detected before onset of clinical symptoms in
macaques. Thus, antibodies from vaccination recognized a small number of proteins shared with pathogenic virus strains,
while recovery from infection also involved humoral responses to antigens uniquely recognized within the monkeypox virus
proteome.
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Introduction
Human monkeypox is a zoonotic disease endemic in Central
and West Africa [1]. The causative agent, monkeypox virus,
belongs to the family Poxviridae, genus Orthopoxvirus. Of the
seven known orthopox species, variola virus causes the most severe
disease (smallpox) and various forms of the attenuated vaccinia
virus are used for vaccination. Skin lesions and other early clinical
manifestations of monkeypox in humans resemble those of
smallpox [2]. In contrast to the human-specific host range of
variola virus, rodents are thought to be a principal natural
reservoir for the monkeypox virus and primates the incidental
hosts of viral circulation [3]. Documented human-to-human
spread of monkeypox [4] indicates the potential for natural
selection of more virulent strains. Compared to smallpox,
monkeypox is less contagious and is therefore geographically
constrained. However, an outbreak of monkeypox occurred in the
United States in 2003 resulting from the transmission of a West
African strain of virus by rodents shipped from Ghana for the pet
trade [5]. West African strains cause death in less than 1% of cases
in Africa but there were no deaths occurring from the US outbreak
and spread of human infection was rapidly contained. In contrast
to West African strains, monkeypox viruses circulating in Central
Africa are more virulent [6,7], with case-fatality rates of
approximately 10% among non-vaccinated individuals [8].
Despite the variability in host tropism and virulence, orthopox
viruses exhibit a high degree of similarity in morphology, life cycle,
and structure of the assembled virus. The approximately 200 kb of
genomic DNA (double-stranded) encodes up to 280 genes, and
replication of the morphologically distinct [9] intracellular mature
virus (IMV) and extracellular enveloped virus (EEV) occurs within
the host cell cytoplasm. The IMV has a physically-robust structure
that facilitates transmission from host to host, while the more
fragile EEV is encased by an envelope designed to limit host
immune clearance and is thus adapted for intercellular spread of
virus. The broad protection provided by vaccination indicates that
orthopox viruses are antigenically related, and that exposure to
one virus may protect from infection by another member of the
family. The classical example of such protection is vaccination
against variola (smallpox) by cowpox or vaccinia infection.
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against monkeypox in a macaque model of disease [10,11].
However, childhood smallpox immunization does not necessarily
provide life-time protection from infection, as some vaccinated
individuals may develop mild to moderate symptoms [12].
The worldwide human population is becoming increasingly
susceptible to smallpox due to the end of routine vaccination in the
1970’s, elevating concern for the increased incidence of mon-
keypox in Africa [13], potential emergence of new virulent strains,
and the threat from bioterrorism. Because of these public health
concerns, there is a need for better diagnostics as well as new safe
and efficacious vaccines. Developing technological tools that bring
a new perspective to our understanding of host responses to
infectious diseases hasten the discovery of new vaccines or
diagnostics. We, and others, have previously used whole proteome
microarrays to measure antibody responses to individual proteins
within the context of entire pathogen proteomes [14–16]. Here we
describe a microarray containing nearly complete protein
collections of both monkeypox and vaccinia viral proteomes,
created with sequence-verified clones, purified protein components
and high quality control. This orthopoxvirus protein microarray
was used to examine potential relationships between antibody
responses to monkeypox virus infection in cynomolgus macaques
and smallpox vaccination in humans.
Methods
Required Ethics Statement
Peripheral arterial blood was collected from healthy human
volunteers at the U.S. Army Medical Research Institute of
Infectious Diseases (USAMRIID) for the preparation of serum,
following written informed consent and in accordance with the
protocol approved by the USAMRIID Institutional Review
Board. Healthy, adult cynomolgus macaques (Macaca fascicularis)
of both sexes were obtained from the USAMRIID animal colony.
All animals exposed to monkeypox virus were handled in a BSL-3
containment laboratory at USAMRIID. Research was conducted
in compliance with the Animal Welfare Act and other federal
statutes and regulations relating to animals and experiments
involving animals, and adhered principles stated in the Guide for
the Care and Use of Laboratory Animals, National Research
Council, 1996. The facility where this research was conducted
(USAMRIID) is fully accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care
International. Research was conducted under a protocol approved
by the Institutional Animal Care and Use Committee (IACUC) at
USAMRIID. All animals were examined and evaluated twice per
day by trained study personnel. Early endpoint criteria, as
specified by the score parameters within the ‘‘Post-exposure
observations’’ section of these methods, were used to determine
when animals should be humanely euthanized to ameliorate any
suffering.
Disease and control sera
Cynomolgus macaques were challenged with controlled
amounts of aerosolized monkeypox virus Zaire-1979_005, and
clinical symptoms were monitored (Nalca et al. manuscript in
preparation). The challenge resulted in lethal infections for
animals that received the highest virus dose and minimal
symptoms in those receiving the lowest dose. Four macaques
challenged with an intermediate level of Zaire-1979_005 (5–
100610
4 pfu) developed symptomatic monkeypox but fully
recovered. We examined this intermediate challenge group in
more detail. Serum samples were collected at days -1, 6, and 28
relative to the challenge date. Sera collected after challenges were
gamma-irradiated (6 Mrad) to destroy any infectious virus.
Previous results indicated minimal damage to serum immuno-
globulins from the sterilizing dose of radiation (data not shown).
Sera were also obtained from four human volunteers previously
vaccinated with a smallpox vaccine (Dryvax,Wyeth) derived from
the New York City Board of Health strain of vaccinia virus and
from three naı ¨ve (non-vaccinated) control individuals. The serum
samples from vaccinated individuals were collected one month
after the last boost.
Proteome microarrays
Proteins encoded by open-reading frames (ORFs) within the
genomes of monkeypox and vaccinia viruses were produced as
described previously [16]. Briefly, ORFs from monkeypox Zaire-
1979_005 (DQ011155; 202 genes), WRAIR7-61 (AY603973; 178
genes), and vaccinia Copenhagen (M35027; 273 genes) were PCR-
amplified, cloned and expressed in Sf9 insect cells using Gateway
baculovirus expression (Invitrogen). All ORF clones were fully
sequenced. Recombinant proteins carried GST-tags and were
affinity purified using glutathione agarose. Purified orthopox
proteins along with a series of positive and negative control
proteins [16] were printed on thin-film nitrocellulose PATH slides
(Gentel Biosciences). Protein spot densities of representative slides
were measured by using an anti-GST antibody and compared to a
dilution series of known quantities of protein also printed on each
slide. Intra-slide and intra-lot variability in spot intensity and
morphology, the number of missing spots and the presence of
control spots were also measured and compared to a defined set of
lot release standards before use in any reported studies. Based on
preliminary assay optimization, microarrays were probed with
serum diluted 1/150 (IgM detection in monkey sera and IgG in
human sera) or 1/500 (IgG in monkey sera). Buffers and assay
conditions were as previously described [15,16]. Antibody binding
was detected by incubation with Alexa-647 labeled goat anti-
human IgG (H+L) and IgM (m chain) at 1/2000 and 1/1000
dilutions, respectively.
Data analysis
Digital images of antibodies interacting with the microarrayed
proteins were collected using a GenePix Pro 6.0 (Molecular
Devices) confocal laser scanner, and data were analyzed using
ProtoArray Prospector 5.1 (Invitrogen) software (Table S1). The
arrays were scanned (power=100) using the highest PMT
(photomultiplier tube) gain setting that did not produce signal
saturation. An M-statistics algorithm (IRBP Toolbox v5.1,
Invitrogen) was used to calculate significance of the results.
Control and disease/vaccinated groups were created with the
IRBP toolbox, and then compared by implementing a minimal
signal of 500 relative fluorescence units (RFU) with a minimal gap
of 200 RFU between signals to determine significant increases in
fluorescent intensity among groups.
Virus neutralization assay
Vero E6 cells (American Type Culture Collection, Manassas,
VA) were suspended in EMEM/NEAA supplemented with 2%
Fetal Bovine Serum (FBS), plated at a concentration of 5610
5 per
well in a 12-well plate, and incubated for 12 h (37uC). One
hundred plaque-forming units of Zaire-1979_005 (ZAIRE),
obtained from cell lysate and supernatant from infected African
green monkey kidney cells (American Type Culture Collection,
Manassas, VA), were added (100 ml EMEM) to macaque sera
serially diluted into 100 ml of EMEM and incubated (37uC, 1 h)
with gentle rocking every 15 min. Medium was removed from
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duplicate wells. Each culture plate also contained cell (media only)
and virus (virus and media) control wells. The plates were mixed
with gentle rocking every 15 min of incubation (37uC, 1 h) and
3 ml of plaquing media (1:1 ratio of 2xEMEM/NEAA with 4%
FBS and methyl cellulose) were added to each well for an
additional 48 h. The plaquing media was removed and Crystal
Violet with 20% MeOH was added to each well to stain for
plaques. Plaques were counted and the 80% plaque reduction
neutralization titer (PRNT80) was determined.
Results
Orthopox proteome microarrays
Gene insertions, truncations, duplications and substitutions of
amino acid residues are common within genomes of monkeypox
virus. For example, within the 194 genes of ZAIRE-96, 514
DNA sequence polymorphisms cause a change in amino acid
composition when compared to all other complete monkeypox
virus strains (average 2.6 amino acids/protein). Because it was
not possible to include every protein variation expressed by all
monkeypox virus strains, the microarray was designed to contain
proteins from two monkeypox strains, ZAIRE and WRAIR7-61
(WRAIR), representing Central and West African clades,
respectively (Table 1). Also included in the microarray were
proteins from a commonly used vaccine strain, vaccinia
Copenhagen (VACCOP). In general the orthopoxvirus strains
represented on the array exhibit a high degree of protein
sequence similarity, with ZAIRE and WRAIR sharing 62
identical proteins. However, only four proteins are identical
among all three strains. For consistency, we use VACCOP
nomenclature for orthologous proteins encoded by monkeypox
virus genomes, and vaccinia Western Reserve for ORFs missing
from VACCOP. We attempted to express all non-identical
proteins from each strain because it was not possible to predict
how minor differences in amino acid sequence translated into
significant alterations of antibody recognition. All ORF clones
isolated for protein expression were sequence-verified through-
out the entire insert length and shuttled into bacmids. Protein
production in eukaryotic cells, via conversion of bacmid clones
into baculovirus for insect cell expression, increased the
likelihood that all products were correctly folded and functional.
Successfully cloned, expressed and size-verified proteins were
contact printed on nitrocellulose-coated glass slides. Statistical
samplings of each printed lot of microarrays were evaluated for
quality and consistency before use in experiments. Combined
coverage of the vaccinia and monkeypox proteomes on the
microarrays was 92–95%.
Detection of antibody responses to pre-symptomatic
monkeypox
Monkeypox is a potentially fatal disease for cynomolgus
macaques. However, challenge with sublethal levels of ZAIRE
virus resulted in a fully-symptomatic disease that was successfully
resolved solely by the immune response of the host without
medical intervention. We examined sera collected before viral
challenge and at several time points leading up to full recovery
from disease, reasoning that this surviving subject group should
harbor the most robust antibody response against monkeypox
virus. Mild anorexia, depression and fever were observed in
macaques no earlier than 6 days after initial infection. Skin rashes
were initially observed beginning on day 8 (amount was
independent of viral challenge dose) and progressed from macules
to papules, then vesicles and pustules to scabs over 10 days.
Lymphadenopathy, which differentiates monkeypox from small-
pox, was first observed in macaques no earlier than 6 days after
initial infection. We first examined the antibody response during
the earliest phase of infection just prior to onset of disease
symptoms by probing the microarrays with sera collected before
(day -1) and 6 days after challenge. Using group data analysis (M-
statistics), we detected increased binding to select arrayed proteins
by IgM from the day 6 sera compared to the day -1 sera across all
animals in the group, while IgG interactions with the orthopox
proteins were negligible. We confirmed significant (p#0.01) IgM
binding to 71 individually arrayed proteins (58 orthologs) in the
day 6 sera compared to the pre-challenge, with 19 proteins
exhibiting more than a fivefold average signal increase (Table 2).
Further, three ZAIRE proteins (Figure 1) exhibited more than a
tenfold increase in IgM binding for day 6 compared to pre-
challenge sera: A44R, an 8.5 Kd protein of unknown function and
the VACCOP envelope proteins F13L and A33R, both expressed
by EEV. Approximately half of the proteins recognized by IgM
were structural elements (envelope or core proteins).
Convalescent IgG responses
We next examined the antibody response following full recovery
from infection by probing the orthopox microarrays with sera
collected before (day -1) and 28 days after challenge, examining
binding of IgG to the orthopoxvirus proteome. There was no IgM
or IgA binding detected with the convalescent sera (data not
shown), indicating that only IgG responses were measurable.
Significant interactions between IgG and 23 independent
orthopoxvirus proteins were detected (Table 3) in convalescent
sera compared to normal sera (M-statistics; minimal signal and
minimal difference of 500 RFUs). The greatest level of IgG
binding occurred with the EEV structural proteins F13L and
Table 1. Orthopoxvirus microarray proteome coverage.
*
Strain
GenBank
Accession # Proteins
Total
encoded
within
genome
Identical to
VACCOP
Identical to
ZAIRE
Identical to
WRAIR
Printed
(% coverage)
VACCOP M35027 273 - 4 4 250 (92)
ZAIRE DQ011155 202 4 - 62 192 (95)
WRAIR AY603973 178 4 62 - 166 (93)
*Protein numbers and identity based on the poxvirus database annotations (www.poxvirus.org).
doi:10.1371/journal.pone.0015547.t001
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two non-structural proteins with relatively high immunogenicity:
WR_148, a protein of unknown function, and the transcriptional
factor H5R. While the IgM response to F13L and A33R that was
detected in acute-phase sera progressed to a convalescent-IgG
response, no significant IgG binding to A44R was detected in sera
from recovered macaques. The biological significance of the
diminished IgG response to A44R is unknown.
Neutralizing antibody and the monkeypox virus
proteome
The results measured up to this point presented a static profile
of proteins that stimulated IgG and IgM responses. To better
understand the physiological relevance of these protein antigens
we examined the neutralization of virus infection in cell culture by
the immune sera, using an assay of plaque-reducing neutralizing
titers (PRNT), focusing on convalescent antibodies. The prepara-
tion of ZAIRE virus for the PRNT assay favored preservation of
predominantly the IMV form due to the fragility of EEV
membranes [9]. Since neutralizing antibodies were expected to
bind mostly IMV surface proteins, we examined IgG in
convalescent sera interacting with the IMV proteins D8L, H3L,
A26L, and A27L (Figure 2A). The total antibody binding of these
IMV surface proteins (Figure 2B) demonstrated a linear
relationship with PRNT80 (R
2=0.67), while interactions of the
individual proteins demonstrated a weaker correlation (R
2=0.05–
0.53). Therefore, the data suggested that antibodies to the four
IMV proteins contribute to virus neutralization. Future studies in
Table 2. Orthopoxvirus proteome recognized by IgM during acute infection.
Vaccinia ortholog Predicted function Fold increase in antibody
a
VACCOP
Virus
ZAIRE WRAIR
F13L EEV phospholipase, envelope protein 14 16 16
d
A44R unknown 5 19 11
A33R EEV envelope protein 7 11 11
d
A46R Toll-IL1-receptor-like protein 5 10 10
C23L chemokine binding protein 7 9 8
A48R thymidylate kinase 5 9 7
B5R EEV envelope protein 7 6 6
d
J1R virion protein required for morphogenesis 9 6 3
E11L core protein 7 5 5
d
A4L core protein 5 5 6
B15R unknown 7 4 5
E3L dsRNA binding protein 7 6 2
WR_146 A-type inclusion protein, fragment NA
b 5N P
c
H3L IMV envelope protein 4 5 5
K7R unknown NP 3 5
B11R unknown 5 2 5
F12L IEV surface protein 2 5 NP
C16L unknown 3 2 5
A26L IMV envelope protein 1 3 5
aProteins exhibiting more than a fivefold average signal increase. Average signals from sera collected at day 6 normalized to average signal at day -1.
bNA, not present in genome,
cNP, not present on array.
d100% identity between WRAIR and ZAIRE proteins.
doi:10.1371/journal.pone.0015547.t002
Figure 1. Acute phase IgM binding to ZAIRE proteins.
Interactions of arrayed orthopox virus proteins with antibody from
serum collected from four macaques (1–4) before (21) and 6 days after
infection with monkeypox virus. Data are presented as mean
fluorescent intensity signal (mean RFUs of 2–4 protein spots). SD,15%.
doi:10.1371/journal.pone.0015547.g001
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physiological relevance of these specific antibody responses to
blocking the spread of infective virus.
Human IgG recognition of the orthopoxvirus proteome
From data obtained with a microarray comprised of the vaccinia
virus proteome, we previously reported [16] that human vaccina-
tion resulted in the induction of IgG that was specific for eight
vaccinia proteins: H5R, C3L, I3L, A27L, D13L, I1L, H3L, and
A33R. Because smallpox vaccination was previously noted to
provide immunity to infections caused by monkeypox virus, we
examined cross-reactivity of the humoral response developed in
humans vaccinated with the Dryvax preparation of vaccinia virus.
Four individuals received two or more vaccinations, with the last
boost occurring one month prior to serum collection. Sera from
unvaccinated individuals (n=3) were used for controls. Collectively,
IgG from these immune sera recognized 14 proteins of monkeypox
virus on the microarray (p#0.03;M-statistics minimal signal of 500,
difference of 200) as presented in Table 4. Notably, all proteins
recognized by IgG from vaccinated humans (Table 4) were also
recognized by macaque serum IgG (Table 3), except for two
proteins with the lowest significant signal: D11L and I4L. While
serum from some vaccinated individuals exhibited significant
PRNT data, overall these results were too low for interpretation,
perhaps due to the reduced ability of anti-vaccinia antibodies to
bind to the heterologous monkeypox virions.
Antibody recognition by protein abundance
All but three (B1R, B2R, and WR_148) of the 25 IgG binding
proteins identified in our study were previously reported in IMV
or EEV (Table 5), as measured by mass spectrometry [17–20].
Nine of the 15 most abundant proteins in the vaccinia IMV, based
on mole % [17,18], demonstrated significant antibody binding
(Table 5). While no correlation (R
2,0) between level of binding
(RFUs) and protein abundance was found (Figure 3), there was a
trend between higher abundance and antibody recognition.
Discussion
Global vaccination with live vaccinia virus resulted in the
successful eradication of smallpox, with Somalia reporting the last
naturally occurring case in 1977. Under pressure from vaccina-
tion, the specificity of variola virus for humans and the absence of
animal or environmental reservoirs were also significant factors
that helped eradicate smallpox. The zoonotic origin of monkeypox
raises concern that the virus may evolve to become more
Table 3. Orthopoxvirus proteome recognized by IgG in convalescent serum.
Vaccinia ortholog Predicted function Fold increase in antibody
a
VACCOP
Virus
ZAIRE WRAIR
F13L EEV envelope protein 387 448 448
b
D13L IV membrane scaffold protein 294 207 72
A33R EEV envelope protein 56 211 211
b
WR_148 A-type inclusion protein, fragment NA
c 119 NP
d
D8L IMV envelope protein 116 161 47
A4L core protein 113 99 88
A27L IMV envelope protein 36 111 149
H3L IMV envelope protein 130 66 93
I1L core protein 81 91 91
b
H5R transcription factor 80 101 70
A10L core protein 124 86 30
E3L dsRNA binding protein 9 101 37
A26L IMV envelope protein 6 86 2
C13L/C14L
e unknown 2/4 62 18
B5R EEV envelope protein 46 33 33
b
B13R/B14R
e serine proteinase inhibitor 3/4 10 49
B19R IFN-alpha/beta receptor 8 37 15
A46R Toll-IL1-receptor [TIR]-like protein 4 28 35
B2R/B3R
e Schlafen 4/2 21 10
C23L chemokine binding protein 17 11 10
L4R core protein 14 10 10
b
B1R Ser/Thr kinase 20 1 1
F17R core protein 6 5 5
b
aAverage signals from sera collected at day 28 normalized to average signal at day -1.
b100% identity between WRAIR and ZAIRE proteins.
cNA, not present in genome.
dNP, not present on array.
eVACCOP proteins orthologous to fragments of a monkeypox protein.
doi:10.1371/journal.pone.0015547.t003
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relatively low transmissibility and virulence. Vaccination against
smallpox reduces lesions and the severity of monkeypox [1,11],
indicating a significant level of cross-reactive immunity. Our
results serve to define the proteomic basis of this common antibody
response to infection by monkeypox virus and smallpox vaccina-
tion. By examining antibodies from ZAIRE-infected macaques we
observed extensive cross-reactivity between the proteomes of
ZAIRE and WRAIR strains, but could not establish any basis for
clade-specific immunity in terms of antibody responses. This is
noteworthy because the distinct virulence and transmissibility
exhibited by the Central and West African monkeypox viruses
represented on the microarrays used in our study may be
independent of host antibody responses. Previous genomic
comparisons between these two dominant clades [6,7,21]
identified several protein candidates that may increase virulence
or alter host immunity thereby leading to differences in clinical
outcome. However, due to the apparent similarity in humoral
responses to monkeypox viruses, our results suggest that further
attenuation of WRAIR or a similar West African strain of virus
may provide broader immunity against severe monkeypox than
currently used vaccinia-based vaccines. While our data collected
with proteome microarrays presents only one facet of poxvirus
immunity, these antibody-mediated responses are essential be-
cause prior studies in macaques demonstrated that depletion of B
cells, but not CD4+ or CD8+ T cells, reversed the protection
Figure 2. IgG responses to ZAIRE IMV envelope proteins contribute to virus neutralization. (A) Antibody binding at days -1 and 28
relative to viral challenge in four macaques (1–4). Mean RFUs of 2–4 protein spots (SD,15%). (B) Correlation between IgG binding to IMV and serum
neutralizing activity. Total antibody binding level to the IMV surface was estimated as the sum of fluorescent intensities for A26L, A27L, D8L, and H3L
and analyzed for association with PRNT80 using linear regression.
doi:10.1371/journal.pone.0015547.g002
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by monkeypox virus [11].
Detection of IgM specific to infection has important diagnostic
implications because it can be used to distinguish acute
monkeypox from the antigen-specific IgG resulting from previous
smallpox vaccinations. The estimated mean human incubation
period for monkeypox virus infection is 12 days [5] and the
optimal timing of specimen collection for determination of IgM
levels using current assays is 7–56 days after appearance of a rash
[22]. Detection of IgM responses earlier than 4 days after rash
onset was problematic in an earlier study that examined
monkeypox viral infection in humans using whole virus in an
ELISA [23]. Our data indicate the possibility of orthopox-specific
IgM detection even before rash onset. In addition, IgM detection
using individual monkeypox proteins in a microarray format may
substantially increase assay sensitivity compared to a whole virus
ELISA. We detected specific IgM responses to monkeypox virus
by 6 days after infection, though earlier time points of sample
collection were not included in the study. Three monkeypox
proteins, orthologs of the vaccinia virus proteins F13L, A33R, and
A44R, exhibited substantial (.106) increases in IgM binding in
the day 6 sera compared to pre-challenge levels. While F13L and
A33R are well-known vaccinia EEV envelope antigens, antibody
recognition of A44R is a new finding. The protein A44R is a 38
amino acid residue fragment of VACCOP (Table 6), whereas the
longer ZAIRE and WRAIR orthologs are closer in length to the
A44R protein of vaccinia Western Reserve, WR_169
(VACCWR). Though the function of this protein is unknown,
A44R contains strings of lysine and aspartic acid residues that
suggest a stable hairpin fold created by salt bonding. About half of
the IgM-binding proteins detected six days after monkeypox
challenge were also recognized by IgG from convalescent sera.
Interestingly, no IgG response was detected against A44R.
Clearly, F13L, A33R, and A44R are potential candidates for
diagnostic tests of acute monkeypox infection (Table 2).
The majority of IgG-binding proteins observed in our study
were previously reported to be present in high amounts within
assembled virions [17–20], though we cannot conclude that
abundance alone favors antibody responses. Previous studies
reported protein targets for neutralizing antibodies on the IMV
surface of vaccinia virus [24,25]. In the results presented here, we
also observed a correlation between the antibody response to the
IMV proteins A26L, A27L, D8L, and H3L with monkeypox virus
neutralization by sera from ZAIRE-infected macaques (Figure 2A).
Further, humans vaccinated with Dryvax demonstrated IgG
responses to the orthopoxvirus proteome that were similar to
those obtained from the serum of macaques recovering from
monkeypox. There were 12 of 14 antigens detected in human
vaccinees that were also recognized by IgG from convalescent sera
of macaques, whereas serum IgG of macaques that recovered from
monkeypox recognized at least 23 separate proteins within the
orthopox proteome. More viral proteins were recognized by
macaque than human antibodies, perhaps because monkeypox
produced a more intense immune response than human
vaccination. Further, our data compared aerosol challenge in
macaques with human skin vaccination. It is possible that
antibodies from humans recovering from monkeypox could
recognize an increased number of antigens compared to
vaccination, though we have not had the opportunity to test this
hypothesis. It should also be noted that group statistical methods
were used to analyze our microarray results, and all significant
antibody interactions that were reported occurred in a majority of
the subjects examined. We did not consider the potential
contribution of variability among individuals in antibody respons-
es, though this is likely to influence the outcome of infection.
Missing from vaccinia strains, the large immunogenic surface
Table 4. Monkeypox virus proteome recognized by IgG from vaccinated humans.
Vaccinia ortholog Predicted function Fold increase in antibody
a
Virus
ZAIRE WRAIR
F13L EEV envelope protein 59 59
b
H3L IMV envelope protein 23 19
I1L DNA binding core protein 55 55
b
D13L IV membrane scaffold protein 28 6
A10L core protein 24 17
A33R EEV envelope protein 17 17
b
A26L IMV envelope protein 20 1
WR_148 A-type inclusion protein, fragment 12 NP
d
A4L core protein 9 11
B5R EEV envelope protein 4 4
b
D8L IMV envelope protein 4 3
B2R/B3R
e Schlafen 5 1
D11L nucleoside triphosphate phosphohydrolase 2 2
I4L ribonucleoside reductase 2 2
aAverage signals in sera of vaccinated normalized to signals in normal sera.
b100% identity between WRAIR and ZAIRE proteins.
cNA, not present in genome.
dNP, not present on array.
eVACCOP proteins orthologous to fragments of a monkeypox protein.
doi:10.1371/journal.pone.0015547.t004
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15547Table 5. Antibody (IgG) responses of convalescent macaque and vaccinated human compared to relative abundance of viral
protein.
Orthopoxvirus
1 protein Predicted Function Known ZAIRE
2 abundance VACCOP
A4L core protein + +
A10L core protein + +
A26L IMV envelope protein + +
A27L IMV envelope protein +
A33R EEV envelope protein + +
A46R Toll-IL1-receptor-like protein +
B1R ser/thr kinase +
B2R/B3R
3 Schlafen + +
B5R EEV envelope protein + +
B13R/B14R
3 serine proteinase inhibitor 2
B19R IFN-alpha/beta receptor 2
C13L/C14L
3 unknown 2
C23L chemokine binding protein 2
D8L IMV envelope protein + +
D11L nucleoside triphosphate phosphohydrolase +
D13L IV membrane scaffold protein + +
E3L dsRNSA binding protein +
F13L EEV phospholipase, envelope protein + +
F17R core protein +
H3L IMV envelope protein + +
H5R transcription factor +
I1L core protein + +
I4L ribonucleoside reductase 2
L4R core protein +
WR_148 A-type inclusion protein, fragment + +
1Bolded orthopox proteins: identified by mass spectometry as one of 15 most abundant proteins, based on mole percent [17].
2Antibody-binding protein, no abundance data available (2). Antibody-binding protein previously measured [17–20] by mass spectrometry (+).
3Vaccinia virus protein similar to protein of monkeypox virus.
doi:10.1371/journal.pone.0015547.t005
Figure 3. Relationship between antibody responses and abundance of IMV proteins. Relative levels of antibody binding were plotted
against the most abundant proteins of vaccinia IMV [refs 17–20], using convalescent macaque and vaccinated human sera.
doi:10.1371/journal.pone.0015547.g003
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distinguishing monkeypox from previous vaccinia vaccination
[26]. However, we did not examine B21R in our study because the
corresponding ZAIRE and WRAIR orthologs were not stably
expressed by insect cells and were therefore missing from the
microarrays. Further, the insect cells we used for protein
production synthesize mostly simple N-glycans with terminal
mannose residues [27], while antibody recognition of the poxvirus
products may be influenced by host protein glycosylation.
Regardless of the glycosylation pattern, the immune response to
saccharides predominantly results in the production of IgM
antibody with little memory component [28], and is thus more
likely to impact analysis of serological responses only during the
acute phase of infection.
There is substantial evidence that antibody responses resulting
from vaccination play a central role in protection against poxvirus
infections. However, the safety and efficacy of current vaccines are
still significant concerns. High-throughput approaches based on
microarrays of the vaccinia virus proteome were recently used to
identify or confirm individual viral proteins associated with
smallpox immunity [14,16]. In addition, these studies revealed
that antibody responses were directed towards a small subset of
antigens contained within the viral proteome [16] and that the
total number of viral proteins recognized by antibodies varied
from person to person, perhaps because specificities of antibody
and CD4+ T cell helper responses were found to be tightly linked
and influenced by HLA class II polymorphism [29]. The technical
advantage that protein microarrays provide to capturing interac-
tions between pathogen and human hosts at the proteomic scale
will prove increasingly more important to understanding the
emergence of new infectious diseases and for devising methods for
medical intervention.
Supporting Information
Table S1 Proteome Microarray Data (Relative Fluores-
cent Units).
(PDF)
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